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Identity 
Other names: ARHGEF31 
HGNC (Hugo): ECT2 
Location: 3q26.31 
Local order: The ECT2 gene is located between the 
RNU4-4P pseudogene in centromeric position and 




The ECT2 gene is composed of 23 exons and spans 
70793 bases on plus strand. 
Transcription 
The ECT2 transcript (NCBI Reference Sequence: 
NM_018098.4) contains 3916 bases and the open 
reading frame spans from 29 to 2680. 17 transcript 
variants have been reported for ECT2. 
Pseudogene 
A pseudogene for ECT2 has not been reported. 
Protein 
Description 
Human ECT2 consist of 883 amino acids, with a 
predicted molecular weight of approximately 104kDa.  
The N-terminus of Ect2 serves regulatory functions and 
contains sequences that exhibit high homology to cell 
cycle control and repair proteins.  
The XRCC1 domain shows sequence homology to 
human XRCC1, a protein that repairs defective DNA 




Location sequence of ECT2 on Chromosome 3. ECT2 gene is indicated by red arrow. 
 
Exon-intron structure of the ECT2 gene. Blue vertical bars correspond to exons, orange represents 3'UTR. 
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Schematic diagram of the domain structure of the Ect2 protein. N, Amino-terminal region; XRCC1, X-ray repair complementing defective 
repair in Chinese hamster cells 1 domain; Cyclin B6, cyclin B6-like domain; BRCT, BRAC1 C-terminal domain; S, small central region; 
NLS, nuclear localization sequence; DH, Dbl homology domain; PH, pleckstrin homology domain; C, Carboxyl-terminal region. 
Phosphorylation on T341 and T412 activate Ect2 during G2/M phase. T328 is phosphorylated by PKCι and required for Ect2 mediated 
transformation in NSCLC cells. 
 
The Clb6 domain shows homology to yeast B-cyclin 
that promotes transition from the G1 to S phase of cell 
cycle. 
The Clb6 domain is followed by sequences that exhibit 
homology to yeast Rad4/Cut5, a protein required for 
entry into S phase and inhibition of M phase entry prior 
to completion of DNA synthesis Rad4/Cut5 also plays 
a critical role in replication checkpoint control in yeast.  
The Cut5 homology domain contains tandem repeats of 
the BRCT (Breast Cancer gene 1 Carboxyl-terminal) 
motif that is conserved in proteins involved in DNA 
repair and cell cycle checkpoint responses. A small 
central (S) domain contains two nuclear localization 
sequences that appear to be involved in the control of 
the intracellular localization of Ect2. The catalytic core 
of Ect2 is found within the C-terminus, and consists of 
a Dbl-homology (DH) and a pleckstrin homology (PH) 
domain which confer guanine nucleotide exchange 
activity toward Rho-GTPases. The extreme C-terminal 
(C) region of Ect2 does not exhibit significant 
homology to any known protein domains or motifs. 
Expression 
Northern blot analysis reveals that Ect2 is expressed in 
a broad range of adult tissues including kidney, liver, 
spleen, testis, lung, bladder, ovary and brain (Miki et 
al., 1993; Saito et al., 2003). In situ hybridization of 
fetal tissues shows Ect2 expression in the liver, thymus, 
proliferating epithelial cells of the nasal cavity and gut, 
tooth primordial, costal cartilage, heart, lung and 
pancreas (Saito et al., 2003). 
Localisation 
Ect2 expression is cell cycle dependent. During 
interphase, Ect2 is sequestered within the nucleus. 
Upon breakdown of the nuclear envelope during 
mitosis, Ect2 is dispersed throughout the cytoplasm. 
Ect2 becomes localized to the mitotic spindles during 
metaphase, the cleavage furrow at telophase, and then 
the mid-body at the end of cytokinesis (Tatsumoto et 
al., 1999). In MDCK cells, small amounts of Ect2 can 
be detected at cell-cell  
contacts where it is reported to directly interact with the 
Par6/Par3/PKCζ polarity complex (Liu et al., 2004). 
Function 
Ect2 is a guanine nucleotide exchange factor and is 
reported to catalyze GTP exchange on several members 
of the Rho GTPase family including, RhoA, RhoB, 
RhoC, RhoG, Rac1 and Cdc42 (Miki et al., 1993; Saito 
et al., 2004; Solski et al., 2004; Tatsumoto et al., 1999; 
Wennerberg et al., 2002). ECT2 regulates cytokinesis 
in mammalian cells through RhoA-mediated pathways 
(Burkard et al., 2007; Kamijo et al., 2006; Kimura et 
al., 2000; Nishimura and Yonemura, 2006; Yuce et al., 
2005). ECT2 associates with GTPase activating 
protein, MgcRacGAP to regulate the activity of RhoA 
which controls contraction of the actomyosin ring and 
ingression of the cleavage furrow required for 
cytokinesis.  
Ect2 has also been implicated in the control of mitotic 
spindle assembly through activation of Cdc42 
(Tatsumoto et al., 2003), and an Ect2→Cdc42→mDia3 
signaling pathway has been implicated in facilitating 
attachment and stabilization of spindle fibers to 
kinetochores (Oceguera-Yanez et al., 2005).  
Ect2 may also play a role in cell polarity. In MDCK 
cells, small amounts of Ect2 can be detected at cell-cell 
contacts where ECT2 is reported to directly interact 
with the polarity complex Par6/Par3/PKCζ and to 
modulate PKCζ activity (Liu et al., 2004). In addition, 
Ect2 was found in the tight junction-containing 
detergent-insoluble fraction of Caco2 cells (Chen et al., 
2012).  
Recently, it has been proposed that ECT2 may 
contribute to neuronal morphological differentiation 
through regulation of growth cone dynamics perhaps 
by directly participating in reorganization of the actin 
cytoskeleton at the tips of neurites (Tsuji et al., 2012). 
Homology 
ECT2 is highly evolutionarily conserved. Homologs of 
ECT2 are present in other mammals as well as aves, 
flies, worms and yeast. 
Mutations 
Note 
Mutations have not been reported for ECT2. 










The ECT2 gene was initially identified as a proto-
oncogene capable of transforming NIH/3T3 fibroblasts 
(Miki et al., 1993). Subsequent analysis revealed that 
the originally characterized oncogenic Ect2 clone 
actually consisted of a carboxyl-terminal truncation of 
the full-length ECT2 gene. This truncated clone 
encoded a protein consisting of the DH-PH-C domains 
of Ect2. This mutant localized to the cytoplasm, 
possessed constitutive GEF activity and could 
transform fibroblasts in vitro (Saito et al., 2004). 
Expression analysis revealed that established human 
cancer cell lines express only full-length Ect2, 
indicating that the transforming C-terminal Ect2 
fragment originally cloned is not directly relevant to 
cancer biology (Saito et al., 2003). Interestingly, full 
length Ect2 is overexpressed in several human tumor 
types, suggesting a role for elevated Ect2 expression in 
these tumors (Hirata et al., 2009; Salhia et al., 2008; 
Sano et al., 2006; Zhang et al., 2008). 
Prognosis 
Ect2 overexpression is associated with poor prognosis 
in patients with non-small cell lung cancer (NSCLC), 
esophageal squamous cell carcinomas (ESCC) (Hirata 
et al., 2009), glioblastoma multiforme (GBM) (Salhia 
et al., 2008; Sano et al., 2006) and oral squamous cell 
carcinomas (OSCC) (Iyoda et al., 2010). 
Cytogenetics 
ECT2 is amplified as part of the 3q26 amplicon a 
region frequently targeted for chromosomal alterations 
in human tumors (Eder et al., 2005; Han et al., 2002; 
Lin et al., 2006; Zhang et al., 2006). ECT2 
amplification frequently occurs in lung squamous cell 
carcinomas (LSCC) (Justilien and Fields, 2009), ESCC 
(Yang et al., 2008; Yen et al., 2005) and cervical cancer 
(Vazquez-Mena et al., 2012). 
Oncogenesis 
Ect2 is overexpressed and mislocalized in human 
tumors 
Ect2 is highly expressed in a variety of human tumors 
including brain (Salhia et al., 2008; Sano et al., 2006), 
lung (Hirata et al., 2009; Justilien and Fields, 2009), 
bladder (Saito et al., 2004), esophageal (Hirata et al., 
2009), pancreatic (Zhang et al., 2008), cervical 
(Vazquez-Mena et al., 2012), colorectal (Jung et al., 
2011), oral (Iyoda et al., 2010) and ovarian tumors 
(Saito et al., 2004). Tumor specific ECT2 gene 
amplification drives Ect2 overexpression in lung 
(Hirata et al., 2009; Justilien and Fields, 2009), 
esophageal (Hirata et al., 2009) and cervical cancers 
(Vazquez-Mena et al., 2012). Ect2 transforming 
activity requires both Ect2 GEF activity and mis-
localization of Ect2 to the cytoplasm (Saito et al., 2004; 
Solski et al., 2004). Immunohistochemical analysis 
demonstrate that Ect2 is predominantly expressed in 
the nucleus of normal lung epithelial cells (Justilien and 
Fields, 2009), but that primary NSCLC tumors display 
increased Ect2 staining in both the nucleus and 
cytoplasm with little or no staining in the tumor-
associated stroma (Hirata et al., 2009; Justilien and 
Fields, 2009). Similarly, Ect2 stains primarily nuclear 
in the low-grade astrocytomas (LGA) whereas 
glioblastoma multiforme (GBMs) display prominent 
staining of Ect2 in both the cytoplasm and nucleus 
(Salhia et al., 2008). OSCCs exhibit strong nuclear and 
cytoplasmic staining of ECT2 staining whereas normal 
oral tissues showed little to no ECT2 staining (Iyoda et 
al., 2010). 
Ect2 is important for transformation in human 
cancer cells 
Ect2 plays a promotive role in transformation in all 
tumor model systems examined to date. Inhibition of 
Ect2 expression by RNAi decreases the proliferation of 
NSCLC (Hirata et al., 2009), ESCC (Hirata et al., 
2009) and OSCC (Iyoda et al., 2010) cells in vitro. In 
addition, stable knockdown (KD) of Ect2 by short 
hairpin RNAs (shRNAs) inhibits anchorage-
independent growth and cellular invasion of multiple 
NSCLC cell lines (Justilien and Fields, 2009) Ect2 KD 
impairs tumor growth of NSCLC cells injected into the 
flanks of athymic nude mice, demonstrating that Ect2 
also plays a role in NSCLC tumorigenicity in vivo 
(Justilien and Fields, 2009). RNAi-mediated 
suppression of Ect2 expression in glioblastoma cells 
caused a significant decrease in cell proliferation and 
migration in vitro and invasion in an ex vivo rat brain 
slice assay (Salhia et al., 2008; Sano et al., 2006). 
Cellular mechanisms in Ect2 mediated 
transformation 
Ect2 function in NSCLC transformation is distinct from 
its well established role in cytokinesis. NSCLC cells 
stably transduced with Ect2 shRNAs do not show 
significant changes in population doubling time (PDT) 
or accumulation of multinucleated cells in vitro or in 
vivo (Justilien and Fields, 2009). NSCLC cells may 
employ an Ect2-independent cytokinesis mechanism 
such as previously described in HT1080 fibrosarcoma 
(Kanada et al., 2008). Whereas Ect2 mediates RhoA 
activity in cytokinesis, Rac1 appears to be the critical 
Ect2 effector in NSCLC. Ect2 KD in NSCLC cells 
leads to a significant decrease in Rac1 activity but no 
apparent changes in Cdc42 or RhoA activity (Justilien 
and Fields, 2009; Justilien et al., 2011). Furthermore, 
expression of a constitutively active Rac1 allele 
(RacV12) restores anchorage independent growth and 
invasion in Ect2 KD cells. 
Co-immunoprecipitation experiments and mass 
spectrometry analysis show that Ect2 associates with 
the PKCι-Par6α complex (Justilien and Fields, 2009; 
Justilien et al., 2011). Ect2 is largely mis-localized to 
the cytoplasm of cultured NSCLC cells and the PKCι-
Par6α complex regulates Ect2 cytoplasmic 
mislocalization (Justilien and Fields, 2009). Ect2 
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isolated from NSCLC cells is highly phosphorylated at 
a novel, previously uncharacterized site T328. PKCι 
directly phosphorylates T328 in vitro and the 
PKCι/Par6 complex regulates T328 phosphorylation in 
intact NSCLC cells. T328 phosphorylation is required 
for ECT2 binding to the PKCι-Par6 complex, Rac1 
activation and transformation in NSCLC cells (Justilien 
et al., 2011). 
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